rdf:type |
|
lifeskim:mentions |
|
pubmed:issue |
8
|
pubmed:dateCreated |
2009-8-19
|
pubmed:abstractText |
The nonnucleoside reverse transcriptase inhibitor (NNRTI) efavirenz undergoes phase I metabolism by the cytochrome P450 enzyme, CYP2B6. Previous studies outside of the United Kingdom have shown associations between the CYP2B6 polymorphism G516T and increased toxicity. This study aimed to develop a CYP2B6 G516T genotyping assay to identify individuals at risk of efavirenz toxicity. The frequency of this polymorphism in a UK HIV-infected population and its prevalence in individuals who had discontinued efavirenz were also to be assessed.
|
pubmed:language |
eng
|
pubmed:journal |
|
pubmed:citationSubset |
IM
|
pubmed:chemical |
|
pubmed:status |
MEDLINE
|
pubmed:month |
Sep
|
pubmed:issn |
1468-1293
|
pubmed:author |
|
pubmed:issnType |
Electronic
|
pubmed:volume |
10
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
520-3
|
pubmed:meshHeading |
pubmed-meshheading:19486190-Adult,
pubmed-meshheading:19486190-African Continental Ancestry Group,
pubmed-meshheading:19486190-Aged,
pubmed-meshheading:19486190-Aged, 80 and over,
pubmed-meshheading:19486190-Aryl Hydrocarbon Hydroxylases,
pubmed-meshheading:19486190-Benzoxazines,
pubmed-meshheading:19486190-Cohort Studies,
pubmed-meshheading:19486190-European Continental Ancestry Group,
pubmed-meshheading:19486190-Female,
pubmed-meshheading:19486190-Gene Frequency,
pubmed-meshheading:19486190-Genotype,
pubmed-meshheading:19486190-Great Britain,
pubmed-meshheading:19486190-HIV Infections,
pubmed-meshheading:19486190-Humans,
pubmed-meshheading:19486190-Male,
pubmed-meshheading:19486190-Medication Adherence,
pubmed-meshheading:19486190-Middle Aged,
pubmed-meshheading:19486190-Oxidoreductases, N-Demethylating,
pubmed-meshheading:19486190-Polymerase Chain Reaction,
pubmed-meshheading:19486190-Polymorphism, Single Nucleotide,
pubmed-meshheading:19486190-Reverse Transcriptase Inhibitors,
pubmed-meshheading:19486190-Young Adult
|
pubmed:year |
2009
|
pubmed:articleTitle |
CYP2B6 G516T genotyping in a UK cohort of HIV-positive patients: polymorphism frequency and influence on efavirenz discontinuation.
|
pubmed:affiliation |
Department of Biochemistry, University Hospitals Bristol NHS Foundation Trust, Bristol Royal Infirmary, Bristol, UK. Victoria.Powers@UHBristol.nhs.uk
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't
|